Recursion Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Recursion Pharmaceuticals
RXRX Stock  USD 3.71  0.14  3.64%   
Recursion Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Recursion Pharmaceuticals' valuation are provided below:
Gross Profit
-503.4 M
Market Capitalization
1.9 B
Enterprise Value Revenue
31.1736
Revenue
43.7 M
Earnings Share
(1.84)
We have found one hundred twenty available trending fundamental ratios for Recursion Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Recursion Pharmaceuticals recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 2.3 B in 2026. Enterprise Value is likely to drop to about 1.9 B in 2026

Recursion Pharmaceuticals Total Revenue

71.05 Million

Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 17.1 M, Interest Income of 19 M or Depreciation And Amortization of 44.1 M, as well as many indicators such as Price To Sales Ratio of 34.42, Dividend Yield of 0.0 or PTB Ratio of 1.69. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Recursion Stock
Check out the analysis of Recursion Pharmaceuticals Correlation against competitors.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Recursion Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.7 B1.7 B478.9 M
Slightly volatile
Short and Long Term Debt Total131 M124.8 M38.5 M
Slightly volatile
Other Current Liabilities98.9 M94.2 M26 M
Slightly volatile
Total Current Liabilities226.4 M215.6 M56.4 M
Slightly volatile
Other Liabilities84.8 M80.8 M25.3 M
Slightly volatile
Property Plant And Equipment Net281.6 M268.2 M79.9 M
Slightly volatile
Accounts Payable26.1 M24.9 M5.7 M
Slightly volatile
Cash394.7 M683.5 M227.1 M
Slightly volatile
Non Current Assets Total886.7 M844.5 M186.5 M
Slightly volatile
Non Currrent Assets Other6.7 M10.1 M3.5 M
Slightly volatile
Other Assets1.091.151.4 M
Pretty Stable
Long Term Debt23 M21.9 M11.9 M
Very volatile
Cash And Short Term Investments437.1 M683.5 M243.2 M
Slightly volatile
Net Receivables59.4 M56.5 M10.7 M
Slightly volatile
Common Stock Shares Outstanding212.6 M315.3 M187 M
Slightly volatile
Liabilities And Stockholders Equity1.7 B1.7 B478.9 M
Slightly volatile
Non Current Liabilities Total154.7 M203.7 M205.3 M
Pretty Stable
Capital Lease Obligations97.9 M93.2 M24.9 M
Slightly volatile
Other Current Assets85.4 M81.4 M22.1 M
Slightly volatile
Other Stockholder Equity3 B2.8 B696.2 M
Slightly volatile
Total Liabilities296.5 M475.9 M260.1 M
Slightly volatile
Property Plant And Equipment Gross357.3 M340.3 M96.1 M
Slightly volatile
Short and Long Term Debt10.2 M9.7 M1.8 M
Slightly volatile
Total Current Assets476.6 M821.4 M269.7 M
Slightly volatile
Net Working Capital393.3 M605.8 M221.9 M
Slightly volatile
Short Term Debt26.8 M25.6 M5.6 M
Slightly volatile
Property Plant Equipment146.6 M139.7 M57.9 M
Slightly volatile
Current Deferred Revenue38.5 M71 M22.6 M
Slightly volatile
Good Will179.8 M171.2 M33.1 M
Slightly volatile
Intangible Assets405.5 M386.2 M69.7 M
Slightly volatile
Common Stock Total Equity1.6 K1.8 K2 K
Slightly volatile
Long Term Debt Total506.4 K569.7 K621.8 K
Slightly volatile
Capital Surpluse754.5 M848.8 M926.5 M
Slightly volatile
Deferred Long Term Liabilities3.3 M3.7 M4 M
Slightly volatile
Non Current Liabilities Other8.3 M4.3 M12.9 M
Slightly volatile
Common Stock2.8 K4.6 K2.3 K
Slightly volatile

Recursion Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income19 M18.1 M5.6 M
Slightly volatile
Depreciation And Amortization44.1 M42 M12.1 M
Slightly volatile
Interest Expense889.5 K1.4 M864.1 K
Slightly volatile
Selling General Administrative215.2 M204.9 M62.5 M
Slightly volatile
Total Revenue71 M67.7 M18.3 M
Slightly volatile
Other Operating Expenses649.4 M618.5 M200.4 M
Slightly volatile
Research Development379.7 M361.6 M124.1 M
Slightly volatile
Cost Of Revenue33.9 M40.7 M43.6 M
Pretty Stable
Total Operating Expenses594.8 M566.5 M186.2 M
Slightly volatile
Reconciled Depreciation44.1 M42 M11.9 M
Slightly volatile
Selling And Marketing Expenses8.3 M9.4 M10.2 M
Slightly volatile

Recursion Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation98.6 M93.9 M22.9 M
Slightly volatile
Begin Period Cash Flow295.9 M461.6 M147.8 M
Slightly volatile
Other Cashflows From Financing Activities7 M7.3 M87.7 M
Slightly volatile
Depreciation44.1 M42 M11.5 M
Slightly volatile
Other Non Cash Items29.3 M28 M6.9 M
Slightly volatile
Capital Expenditures20.8 M15.7 M10.9 M
Slightly volatile
Issuance Of Capital Stock267.6 M345.5 M185.4 M
Slightly volatile
Total Cash From Financing Activities261 M349.7 M183.4 M
Slightly volatile
End Period Cash Flow403.6 M693.5 M233.8 M
Slightly volatile
Change To Netincome47.4 M45.2 M14.8 M
Slightly volatile
Change To Inventory1.7 K1.8 K3.3 M
Slightly volatile
Sale Purchase Of Stock377.1 M424.2 M463 M
Slightly volatile
Change Receivables91.2 K102.6 K112 K
Slightly volatile
Cash And Cash Equivalents Changes22.5 M25.4 M27.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio34.4236.231.1 K
Slightly volatile
Days Sales Outstanding28827493.4921
Slightly volatile
Stock Based Compensation To Revenue0.911.250.9593
Slightly volatile
Capex To Depreciation0.410.431.5903
Pretty Stable
EV To Sales25.426.731.1 K
Slightly volatile
Payables Turnover2.292.4124.2601
Slightly volatile
Sales General And Administrative To Revenue5.843.488.2858
Slightly volatile
Research And Ddevelopement To Revenue5.846.1519.2098
Slightly volatile
Capex To Revenue0.250.271.8101
Slightly volatile
Cash Per Share1.631.951.1526
Slightly volatile
Days Payables Outstanding16515743.2053
Slightly volatile
Income Quality0.790.890.8395
Slightly volatile
Intangibles To Total Assets0.320.30.0699
Slightly volatile
Net Debt To EBITDA1.831.311.2568
Slightly volatile
Current Ratio4.164.389.4135
Slightly volatile
Receivables Turnover1.311.389.9277
Slightly volatile
Capex Per Share0.080.04490.0562
Slightly volatile
Revenue Per Share0.20.190.072
Slightly volatile
Interest Debt Per Share0.380.360.1693
Slightly volatile
Debt To Assets0.08360.08610.1212
Slightly volatile
Operating Cycle28827493.4921
Slightly volatile
Days Of Payables Outstanding16515743.2053
Slightly volatile
Ebt Per Ebit1.091.121.0037
Slightly volatile
Effective Tax Rate0.00260.00280.0105
Slightly volatile
Quick Ratio4.164.389.4135
Slightly volatile
Net Income Per E B T1.11.151.0178
Slightly volatile
Cash Ratio3.463.658.3517
Slightly volatile
Days Of Sales Outstanding28827493.4921
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.291.191.1232
Slightly volatile
Fixed Asset Turnover0.180.230.1378
Slightly volatile
Debt Ratio0.08360.08610.1212
Slightly volatile
Price Sales Ratio34.4236.231.1 K
Slightly volatile
Asset Turnover0.02780.03660.025
Slightly volatile

Recursion Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.4 B2.7 B
Slightly volatile
Enterprise Value1.9 B2 B2.3 B
Slightly volatile

Recursion Fundamental Market Drivers

Recursion Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Recursion Pharmaceuticals Financial Statements

Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue71 M38.5 M
Total Revenue67.7 M71 M
Cost Of Revenue40.7 M33.9 M
Stock Based Compensation To Revenue 1.25  0.91 
Sales General And Administrative To Revenue 3.48  5.84 
Research And Ddevelopement To Revenue 6.15  5.84 
Capex To Revenue 0.27  0.25 
Revenue Per Share 0.19  0.20 
Ebit Per Revenue(7.33)(7.69)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY